biostudies-literatureJohnson SAUK Coronavirus Immunology ConsortiumHuo Family FoundationMedical Research CouncilNational Institute for Health Research (NIHR)U.S. Food and Drug Administration249-261https://www.ebi.ac.uk/biostudies/studies/S-EPMC10243914biostudies-literatureUnknown212(3)T cells are important in preventing severe disease from SARS-CoV-2, but scalable and field-adaptable alternatives to expert T-cell assays are needed. The interferon-gamma release assay QuantiFERON platform was developed to detect T-cell responses to SARS-CoV-2 from whole blood with relatively basic equipment and flexibility of processing timelines. Forty-eight participants with different infection and vaccination backgrounds were recruited. Whole blood samples were analysed using the QuantiFERON SARS-CoV-2 assay in parallel with the well-established 'Protective Immunity from T Cells in Healthcare workers' (PITCH) ELISpot, which can evaluate spike-specific T-cell responses. The primary aims of this cross-sectional observational cohort study were to establish if the QuantiFERON SARS-Co-V-2 aClinical and experimental immunologyEvaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination.PMC10243914MR/X009297/1NF-SI-0617-10139NIHR20379275F40120C00085NIHR300791COVID-19-RECPLASACF-2018-13-005CL-2020-13-002Longet SCarroll MWhite JWilson JDKronsteiner BMason CJamsen AGoulder PSkelly DTConlon CPNeo JKlenerman PJohnson SAGardiner SPhillips EBlurton EJAli MDeeks AMalone TJeffery KStafford LDunachie SJAdele SConsortium PBarnes EfalseEvaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination.T cells are important in preventing severe disease from SARS-CoV-2, but scalable and field-adaptable alternatives to expert T-cell assays are needed. The interferon-gamma release assay QuantiFERON platform was developed to detect T-cell responses to SARS-CoV-2 from whole blood with relatively basic equipment and flexibility of processing timelines. Forty-eight participants with different infection and vaccination backgrounds were recruited. Whole blood samples were analysed using the QuantiFERON SARS-CoV-2 assay in parallel with the well-established 'Protective Immunity from T Cells in Healthcare workers' (PITCH) ELISpot, which can evaluate spike-specific T-cell responses. The primary aims of this cross-sectional observational cohort study were to establish if the QuantiFERON SARS-Co-V-2 a2023-01-01T00:00:00Z2023 Jun2026-06-20T03:14:35.37Z2025-04-04T14:40:04.637ZS-EPMC102439143680749910.1093/cei/uxad027